How immersive technology could drive the future of healthcare

How immersive technology could drive the future of healthcare

Jeffrey Tan
11/01/19, 11:39 am

SINGAPORE (Jan 11): Immersive technology is ­increasingly being deployed in various fields other than electronic games and entertainment. 

Take medicine for example, where Singapore start-up BetaSight is using virtual reality (VR) headsets to make the diagnosis of glaucoma easier. 

Glaucoma is an eye condition in which the optic nerve is damaged as a result of ­abnormally high pressure in the eye. If the damage continues, it can cause permanent vision loss. 

BetaSight’s solution tracks a patient’s eye movements in response to pop-up virtual objects generated by the VR headset.

According to BetaSight’s founders, the current process of diagnosis can be taxing and lead to skewed results. One of the start-up’s investors even had to take the test twice, and was charged double the price.

With BetaSight’s VR headsets, patients do not have to sit still or press any buttons – unlike the traditional procedure which uses a visual field analyser.

Instead, they only have to put on the VR headset and track the virtual objects with their eyes, which is more intuitive than pressing a button. A person who has glaucoma will have a diminished field of vision and not be able to spot all of the virtual objects.

The VR headset is portable and considerably less bulky than the visual field analyser equipment in use today.

In our latest issue of The Edge Singapore (Issue 864, week of Jan 14), Betasight’s founders Martin Sawtell and Corey Manders tell us how they first came up with the idea of using VR technology to diagnose glaucoma, as well as discuss the enormous potential of VR and AR technologies.

Login to read the full story, BetaSight develops better vision test using virtual reality headsets, or click here to subscribe.

Right timing: STI stays intact, but Hong Fok is at extreme overbought high

SINGAPORE (Mar 23): Although quarterly momentum appears ambivalent as it is consolidating beneath its own moving average, prices are intact. They have established support at the confluence of the 50- and 200-day moving averages which are moving into an increasingly positive stance at 3,217 and 3,186 respectively. The index may well be able to regain its 50-day moving average as short term stochastics is turning up from the bottom of its range. Since medium term indicators are neutral and drifting sideways, short term indicators could keep the STI afloat. However the range is likely to be ....

EY Singapore launches 18th edition of Entrepreneur Of The Year awards

SINGAPORE (Mar 22): The search has started for the 18th EY Entrepreneur Of The Year, as part of the bid to promote entrepreneurship and shape a new role model for the business community. Ernst & Young LLP, organiser of the annual awards, observes that entrepreneurs in Singapore, and the world, have built some of the world’s most enduring companies. The businesses they build don’t just create employment and contribute to the GDP. “Their creativity, tenacity and courage serve as an inspiration for many. In many ways, the way they overcome the odds, the power of their influence, a....

Challenger Tech's 2.94% shareholder says offer price too low, calls for higher dividend payouts

SINGAPORE (Mar 22): Pangolin Investment Management, which holds a 2.94% stake in Challenger Technologies through its Pangolin Asia Fund, is calling on other shareholders to reject Digileap Capital’s delisting offer at the company’s upcoming EGM.   Pangolin says the offer price of 56 cents per share, which translates to a price-to-earnings ratio of 9.9 times, is too low and thus unfair to minority shareholders. In a letter sent to The Edge Singapore on Friday, Pangolin explains its reasons for strongly advising other Challenger shareholders to reject the offer, which it deems “....